| TARGET | |
|---|---|
| SYNONYMS |
B7DC;bA574F11.2;Btdc;CD273;PD-L2;PDCD1L2;PDL2 |
| DESCRIPTION |
Recombinant human PDL2 protein with C-terminal 6×His tag |
| DELIVERY |
In Stock |
| UNIPROT ID |
Q9BQ51 |
| EXPRESSION HOST |
HEK293 |
| TAG |
C-6×His Tag |
| MOLECULAR CHARACTERIZATION |
PDL2(Leu20-Pro219) 6×His tag |
| MOLECULAR WEIGHT |
The protein has a predicted molecular mass of 23.4 kDa after removal of the signal peptide.The apparent molecular mass of PDL2-His is approximately 35-55 kDa due to glycosylation. |
| PURITY |
The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining. |
| FORMULATION & RECONSTITUTION |
Lyophilized from sterile PBS, pH 7.4. Normally 5 % – 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| STORAGE & SHIPPING |
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| BACKGROUND |
Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production (By similarity).[UniProtKB/Swiss-Prot Function] |
| USAGE |
Research use only |
Dima Biotech
SKU(재고 관리 코드):PME100518
Human PDL2 Protein, His Tag
Human PDL2 Protein, His Tag
PRODUCT DATA
IMAGES
Figure 1. Human PDL2 Protein, His Tag on SDS-PAGE under reducing condition.
Figure 2. Flow cytometry analysis with 15 μg/mL Human PDL2 Protein, His tag (PME100518) on Expi293 cells transfected with human PD1 (Blue histogram) or Expi293 transfected with irrelevant protein (Red histogram).
Figure 3. ELISA plate pre-coated by 2 μg/mL (100 μL/well) Human PDL2 Protein, His Tag (PME100518) can bind Anti-PDL2 antibody(DM169), Rabbit mAb in a linear range of 0.13–3.20 ng/mL.
